Point Therapeutics Announces Annual Meeting of Stockholders on July 20, 2005 in Boston - Meeting will be Web cast

Point Therapeutics, Inc. (NASDAQ:POTP) announced that it
will hold its Annual Meeting of Stockholders on July 20, 2005 at 11:00
a.m., Eastern Time. All shareholders are invited to attend the meeting
which will be held at the offices of Ropes & Gray, LLP, One
International Place, 36th Floor, Boston, MA, 02110.
   After completion of the formal portion of the annual meeting,
Donald Kiepert, Founder, Chairman, CEO and President will review
company achievements and discuss future company objectives.
   The meeting will also be Web cast on the company's Web site,
www.pointtherapeutics.com at 11:00 a.m., Eastern Time, July 20, 2005.
A replay will be available on www.pointtherapeutics.com following the
meeting.

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
family of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Its lead product candidate,
talabostat (PT-100), is a small molecule drug in Phase 2 clinical
trials. Talabostat is orally-active and, through a novel mechanism of
action, has the potential to inhibit the growth of malignant tumors
and to support the reconstitution of the hematopoietic system. In
2004, Point initiated four Phase 2 clinical trials of talabostat. The
trials are studying talabostat in combination with docetaxel in
metastatic non-small cell lung cancer, talabostat as a single agent in
metastatic melanoma, talabostat in combination with cisplatin in
metastatic melanoma, and talabostat in combination with rituximab in
advanced chronic lymphocytic leukemia. In June of 2005, Point
announced the initiation of a fifth Phase 2 clinical trial studying
talabostat in combination with gemcitabine in metastatic pancreatic
cancer. In addition, Point's portfolio includes two other DPP
inhibitors in preclinical development--PT-630 for type 2 diabetes, and
PT-510 as a vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements on the prospects for our drug development activities and
results of operations based on our current expectations, such as
statements regarding certain milestones with respect to our clinical
program and our product candidates. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "expects," "may," "will," "should," "seeks," "plans,"
"schedule to," "anticipates" or "intends" or the negative of those
terms, or other variations of those terms of comparable language, or
by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those
projected or suggested in the forward looking statement, including,
but not limited to, the ability of Point to (i) successfully develop
and manufacture products, (ii) obtain external funding to finance the
operations, (iii) obtain the necessary regulatory approvals, and (iv)
obtain and enforce intellectual property rights, as well as the risk
factors described in Point's Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on May 10, 2005 and from time
to time in Point's other reports filed with the Securities and
Exchange Commission.